Cara Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Cara Therapeutics, Inc. filed its quarterly report (10-Q) for the period ending March 31, 2024.</b>

AI Summary

Cara Therapeutics, Inc. (TVRD) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Cara Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024. The company's fiscal year ends on December 31st. Cara Therapeutics, Inc. is incorporated in Delaware. The company's business address is 400 Atlantic Street, Suite 500, Stamford, CT 06901. The filing is a 10-Q, indicating a quarterly report.

Why It Matters

For investors and stakeholders tracking Cara Therapeutics, Inc., this filing contains several important signals. This 10-Q filing provides an update on Cara Therapeutics' financial performance and operational status for the first quarter of 2024. Investors and stakeholders can use this report to assess the company's progress, evaluate its financial health, and make informed investment decisions.

Risk Assessment

Risk Level: low — Cara Therapeutics, Inc. shows low risk based on this filing. The filing is a standard quarterly report (10-Q) and does not contain any immediate red flags or significant negative developments.

Analyst Insight

Monitor future 10-Q and 10-K filings for detailed financial performance, revenue growth, and updates on product development pipelines.

Key Numbers

• 2024-03-31 — Period End Date (Conformed period of report)
• 2024-05-13 — Filing Date (Filed as of date)
• 10-Q — Form Type (SEC Filing Form Type)
• 001-36279 — SEC File Number (SEC File Number)

Key Players & Entities

• Cara Therapeutics, Inc. (company) — Filer name
• 2024-03-31 (date) — Conformed period of report
• 2024-05-13 (date) — Filed as of date
• 0001346830 (company) — Central Index Key
• 2834 (industry) — Standard Industrial Classification
• DE (state) — State of incorporation
• 1231 (date) — Fiscal year end
• 203-406-3700 (phone) — Business phone

FAQ

Industry Context

Cara Therapeutics, Inc. operates in the pharmaceutical preparations industry, focusing on the development and commercialization of novel, peripherally acting, selective opioid receptor antagonists.

Regulatory Implications

The company is subject to standard SEC regulations for public companies, including the requirement to file quarterly reports (10-Q) and annual reports (10-K).

What Investors Should Do

1. Review the full 10-Q filing for detailed financial statements and management discussion.
2. Analyze any disclosed risk factors or legal proceedings.
3. Track future SEC filings for updates on clinical trials and product development.

Key Dates

• 2024-03-31: Quarterly Period End — End of the reporting period for the 10-Q filing.
• 2024-05-13: Filing Date — Date the 10-Q report was officially filed with the SEC.

Year-Over-Year Comparison

This is the first 10-Q filing for the fiscal year 2024, providing an update from the previous year's filings.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share CARA The Nasdaq Stock Mar

Filing Documents

• cara-20240331x10q.htm (10-Q) — 1724KB
• cara-20240331xex31d1.htm (EX-31.1) — 12KB
• cara-20240331xex31d2.htm (EX-31.2) — 11KB
• cara-20240331xex32d1.htm (EX-32.1) — 11KB
• 0001558370-24-007964.txt (&nbsp;) — 8363KB
• cara-20240331.xsd (EX-101.SCH) — 66KB
• cara-20240331_cal.xml (EX-101.CAL) — 58KB
• cara-20240331_def.xml (EX-101.DEF) — 289KB
• cara-20240331_lab.xml (EX-101.LAB) — 517KB
• cara-20240331_pre.xml (EX-101.PRE) — 439KB
• cara-20240331x10q_htm.xml (XML) — 1449KB

–FINANCIAL INFORMATION

PART I –FINANCIAL INFORMATION PAGE NUMBER Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) : Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023 1 Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2024 and 2023 2 Condensed Consolidated Statements of Stockholders' Equity for the Three Months Ended March 31, 2024 and 2023 3 Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2024 and 2023 4 Notes to Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 29 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 53 Item 4.

Controls and Procedures

Controls and Procedures 54

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 55 Item 1A .

Risk Factors

Risk Factors 55 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 55 Item 3. Defaults Upon Senior Securities 55 Item 4. Mine Safety Disclosures 55 Item 5. Other Information 55 Item 6. Exhibits 56

SIGNATURES

SIGNATURES 57 Table of Contents PART I FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements . CARA THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (amounts in thousands, excluding share and per share data) (unaudited) March 31, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 46,996 $ 51,775 Marketable securities 22,777 48,983 Accounts receivable, net - related party 1,718 2,765 Inventory, net 2,741 2,821 Income tax receivable 697 697 Other receivables 506 555 Prepaid expenses 5,790 8,154 Restricted cash — 408 Total current assets 81,225 116,158 Operating lease right-of-use assets 3,826 4,864 Property and equipment, net 3,548 3,322 Restricted cash, non-current 1,500 1,500 Total assets $ 90,099 $ 125,844 Liabilities and stockholders' equity Current liabilities: Accounts payable and accrued expenses $ 14,875 $ 25,592 Operating lease liability, current 220 — Total current liabilities 15,095 25,592 Liability related to sales of future royalties and milestones, net 38,376 37,079 Operating lease liability, non-current 6,825 6,088 Total liabilities 60,296 68,759 Commitments and contingencies (Note 17) — — Stockholders' equity: Preferred stock; $ 0.001 par value; 5,000,000 shares authorized at March 31, 2024 and December 31, 2023, zero shares issued and outstanding at March 31, 2024 and December 31, 2023 — — Common stock; $ 0.001 par value; 100,000,000 shares authorized at March 31, 2024 and December 31, 2023, 54,667,079 shares and 54,480,704 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively 54 54 Additional paid-in capital 745,381 742,036 Accumulated deficit ( 715,441 ) ( 684,745 ) Accumulated other comprehensive loss ( 191 ) ( 260 ) Total stockholders' equity 29,803 57,085 Total liabilities and stockholders' equity $ 90,099 $ 125,844 See Notes to Condensed Consolidated Financial Statements. 1 Table of Contents

View Full Filing

View this 10-Q filing on SEC EDGAR